利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.024 秒)

    POLYPEPTIDES
    3.
    发明申请
    POLYPEPTIDES 审中-公开
    多肽

    公开(公告)号：WO2016156468A1

    公开(公告)日：2016-10-06

    申请号：PCT/EP2016/057024

    申请日：2016-03-31

    申请人： VHSQUARED LIMITED

    发明人： CROWE, Scott ,  WEST, Mike ,  ROBERTS, Kevin ,  CARLTON, Tim

    IPC分类号： C07K16/12 ,  C07K16/24

    CPC分类号： C07K16/1282 ,  A61K2039/542 ,  C07K16/241 ,  C07K16/2866 ,  C07K2317/22 ,  C07K2317/35 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  Y02A50/484

    摘要： There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1 -CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue; wherein the polypeptide has increased intestinal stability relative to a corresponding polypeptide not having said histidine substitutions.

    摘要翻译： 提供了包括包含三个互补决定区（CDR1-CDR3）和四个框架区的免疫球蛋白链可变结构域的多肽，其中：（a）CDR1，CDR2和/或CDR3中的至少一个赖氨酸残基已被 至少一个组氨酸残基和/或（b）CDR1，CDR2和/或CDR3中的至少一个精氨酸残基已被至少一个组氨酸残基取代; 其中相对于不具有所述组氨酸取代的相应多肽，所述多肽具有增加的肠稳定性。

    POLYPEPTIDES
    7.
    发明申请
    POLYPEPTIDES 审中-公开

    公开(公告)号：WO2020254826A1

    公开(公告)日：2020-12-24

    申请号：PCT/GB2020/051495

    申请日：2020-06-19

    申请人： VHSQUARED LIMITED

    发明人： CROWE, Scott ,  CUBITT, Marion ,  CARLTON, Tim ,  MAGGIORE, Luana ,  DUARTE, Lurdes ,  ROBERTS, Kevin ,  WEST, Mike

    IPC分类号： C07K16/24

    摘要： There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.